Anti-myoglobin antibody and kit
A myoglobin and antibody technology, applied in the field of anti-myoglobin antibodies and kits
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0112] In this example, the restriction endonuclease and Prime Star DNA polymerase were purchased from Takara Company. MagExtractor-RNA extraction kit was purchased from TOYOBO Company. BD SMART TM RACE cDNA Amplification Kit was purchased from Takara Company. The pMD-18T vector was purchased from Takara Company. Plasmid extraction kit was purchased from Tiangen Company. Primer synthesis and gene sequencing were performed by Invitrogen.
[0113] 1 Construction of recombinant plasmids
[0114] (1) Antibody gene preparation
[0115] The mRNA was extracted from the hybridoma cell line (11D2) secreting anti-myoglobin monoclonal antibody, and the DNA product was obtained by RT-PCR method, and the product was inserted into the pMD-18T vector after adding A reaction with rTaq DNA polymerase, Transform into DH5α competent cells, and after the colonies grow out, take 4 clones of Heavy Chain and Light Chain gene clones and send them to a gene sequencing company for sequencing.
...
Embodiment 2
[0136] Antibody performance testing
[0137] (1) Activity detection of the antibody and its mutants in Example 1
[0138] Further analysis, the heavy chain variable region of the myoglobin monoclonal antibody (WT) of Example 1 is shown in SEQ ID NO: 12, wherein, wherein, the amino acid sequence of each complementarity determining region is as follows:
[0139] CDR1-VH: G-Y-S(X1)-F-T-S(X2)-Y-I(X3)-M-H;
[0140] CDR2-VH: Y-I(X1)-H(X2)-P-Y-Q(X3)-Y-D-T-K-Y-N-D(X4)-K-F;
[0141] CDR3-VH: A(X1)-R-G-G-N(X2)-F;
[0142] Its light chain variable region is shown in SEQ ID NO: 11, wherein the amino acid sequence of each complementarity determining region of the light chain is as follows:
[0143] CDR1-VL: S(X1)-A-S-S-S-V(X2)-Y-P-S-Y-I(X3)-Y;
[0144] CDR2-VL: T-T-S-Q(X1)-I(X2)-A-S;
[0145] CDR3-VL: H(X1)-Q-W(X2)-H-R-S-R.
[0146] On the basis of the myoglobin monoclonal antibody in Example 1, mutations were carried out at sites related to antibody activity in the complementarity d...
PUM
| Property | Measurement | Unit |
|---|---|---|
| affinity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


